Human Plasmin Reference standard

• Cat.No.: PLG-161H
• Product Overview: The Standard for plasmin, consists of ampoules containing the residue after freeze-drying of a solution of a highly purified preparation of human plasmin admixed with human albumin, lactose and buffer salts. The potency was assigned as the geometric mean of all valid assays in all laboratories, giving a value of 5.3 IU per ampoule..

Specification

• Species: Human
• Enzyme Unit: 5.3 IU per ampoule.
• Notes: This preparation is not for administration to humans. The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratorys safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.
• Stability: Reference materials are held at Creative Biomart within assured, temperature- controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label. A physiological assay using fibrin in a clot lysis assay was used at Creative Biomart to assess the loss of potency in degradation samples stored at elevated temperatures for 38 weeks, as well as the chromogenic procedure. The clot lysis assay was specifically used because of earlier observations that loss of enzymatic activity due to heat degradation is best measured using a natural substrate such as fibrin. The clot lysis assays appear to detect some degradation at +37°C and +45°C. For the clot lysis assays, the long term stability of the proposed Standard for plasmin was predicted using the Arrhenius equation. The predicted losses are 0.79% per year at the storage temperature of -20°C and 1.94% per month at 37°C. Since the assay in routine use is the chromogenic assay the degradation from such assays was also used to assess stability for 38 weeks.
• Storage: Unopened ampoules should be stored in the dark at or below –20°C. Please note: because of the inherent stability of lyophilized material, Creative Biomart may ship these materials at ambient temperature.
• Tag: Non

Gene Information

• Gene Name: PLG plasminogen [ Homo sapiens ];
• Official Symbol: PLG
• Synonyms: PLG; plasminogen; plasmin; DKFZp779M0222
• Gene ID: 5340
• mRNA Refseq: NM_001168338
• Protein Refseq: NP_001161810
• MIM: 173350
• UniProt ID: P00747
• Chromosome Location: 6q26
• Pathway: Activation of Matrix Metalloproteinases, organism-specific biosystem; Angiopoietin receptor Tie2-mediated signaling, organism-specific biosystem; Blood Clotting Cascade, organism-specific biosystem; Complement and Coagulation Cascades, organism-specific biosystem; Complement and coagulation cascades, organism-specific biosystem; Complement and coagulation cascades, conserved biosystem; Degradation of the extracellular matrix, organism-specific biosystem
• Function: apolipoprotein binding; cell surface binding; peptidase activity; protein binding; protein domain specific binding; serine-type endopeptidase activity

Reviews

06/12/2022

The tightly sealed packaging of this protein reagent ensures optimal preservation of its activity.

11/18/2021

I highly recommend this reagent for its simplified experimental workflow, saving time and experimental costs.

08/10/2019

Catering to diverse experimental needs, its outstanding performance facilitates diversity in scientific research.

Q&As

What is the clinical significance of PLG as a diagnostic or prognostic biomarker?

PLG has been investigated as a potential diagnostic and prognostic biomarker for various diseases. For instance, altered PLG levels have been observed in cancer patients, serving as a potential marker for tumor progression and prognosis. Additionally, PLG has been implicated in cardiovascular diseases, where its levels can reflect the severity of certain conditions, such as thrombosis. Moreover, PLG may have utility as a biomarker in inflammatory disorders and neurological diseases. Further research is needed to validate the clinical utility of PLG as a biomarker and develop specific assays for its detection.

What are the pathological implications of PLG dysregulation?

Dysregulation of PLG has been associated with several pathological conditions. Decreased PLG levels or impaired activation can lead to impaired fibrinolysis, resulting in the formation of excessive blood clots. On the other hand, increased PLG activation or excessive Plasmin activity can promote tissue degradation, contributing to diseases such as chronic inflammation, cancer metastasis, and tissue damage. Moreover, PLG has been implicated in the pathogenesis of neurodegenerative disorders and cardiovascular diseases. Understanding the mechanisms underlying PLG dysregulation is crucial for designing therapeutic strategies to counteract its pathological implications.

What therapeutic strategies target PLG for the treatment of diseases?

PLG-targeted therapeutic strategies have shown promise in various diseases. For example, agents that enhance PLG activation, such as tPA and uPA, have been employed to promote fibrinolysis and dissolve blood clots in conditions such as heart attacks and ischemic strokes. Conversely, inhibitors of PLG activation, such as PAIs, can be used to prevent excessive fibrinolysis and subsequent bleeding complications. Additionally, targeting PLG receptors or manipulating PLG interactions with other molecules may offer potential therapeutic avenues. However, further research is required to optimize these strategies and assess their efficacy and safety in clinical settings.

What is the full name and structure of the PLG protein?

The PLG protein, also known as Plasminogen, is a single-chain glycoprotein composed of 790 amino acids. It consists of several domains, including a signal peptide, five kringle domains (K1-K5), and a serine protease domain. The signal peptide mediates protein secretion, while the kringle domains have numerous functions, such as binding to receptors and ligands. The serine protease domain is responsible for the conversion of Plasminogen to active Plasmin, a crucial enzyme in fibrinolysis and extracellular matrix remodeling processes.

What are the physiological functions of PLG in the human body?

PLG plays a vital role in several physiological processes. Its primary function is as a precursor to Plasmin, which is involved in the degradation of blood clots (fibrinolysis). Plasmin also participates in tissue remodeling, wound healing, and cell migration. Additionally, PLG has been implicated in immune responses, angiogenesis, and cell adhesion. Its ability to interact with various receptors and bind to components of the extracellular matrix highlights its diverse and important functions in maintaining normal physiological homeostasis.

What is the biological function of PLG?

PLG, also known as plasminogen, plays a crucial role in the fibrinolytic system. Its main biological function is to be converted into plasmin, an enzyme that breaks down fibrin clots. Plasminogen is activated by tissue plasminogen activator (tPA), which cleaves it into active plasmin. Plasmin then degrades fibrin clots, preventing the formation of thrombi and promoting the dissolution of existing blood clots. Additionally, PLG is involved in various physiological processes, such as wound healing, tissue remodeling, cell migration, and inflammation.

How is the activation of PLG regulated?

The activation of PLG is tightly regulated to prevent undesired fibrinolysis. Activation can occur through two main pathways: the tissue-type Plasminogen Activator (tPA)-dependent pathway and the urokinase-type Plasminogen Activator (uPA)-dependent pathway. In the tPA-dependent pathway, tPA binds to a specific receptor on the cell surface and catalyzes the conversion of PLG to Plasmin. The uPA-dependent pathway involves uPA binding to a receptor, followed by the activation of PLG. Additionally, various regulatory proteins, such as Plasminogen Activator Inhibitors (PAIs), control PLG activation by inhibiting the activity of tPA and uPA.